23-Jun-2022 - Iktos

Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design

Collaboration leverages Iktos’ capabilities in machine learning and AI and Zealand expertise in peptide drug discovery

Iktos, a company specialized in Artificial Intelligence for new drug design, announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug design.

Iktos’ AI technology, based on a comprehensive data-driven chemical structure generation technology, brings new insights into the drug discovery process. This technology automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. Iktos has recently diversified its R&D efforts into the development of an AI technology for peptide-based therapeutics and has developed state-of-the-art generative and predictive models to facilitate design of novel peptide therapeutics with desired properties.

Zealand Pharma A/S has a track record of successfully inventing and developing novel peptide-based drugs. This success is based on the extensive experience in improving the therapeutic characteristics of peptides. Zealand Pharma has a keen interest in expanding its computational chemistry toolbox to include AI and machine learning based approaches for the design of novel therapeutic peptides.

Under the agreement, Zealand will contribute its expertise in peptide drug discovery to Iktos’ generative modelling technologies and expertise in machine learning and AI.

“We are very pleased to join forces with Zealand Pharma and leverage their deep know-how in peptide therapeutics with our state-of-the-art existing technology assets to peptide drug discovery” commented Yann Gaston-Mathé, President and CEO of Iktos. “We look forward to working with Zealand’s experienced R&D team to build leading/state of the art peptide generative and predictive modelling technology in the field of peptides - a new area for Iktos.”

Facts, background information, dossiers
More about Iktos
  • News

    French start-up Iktos announces a collaboration with Ono in artificial intelligence for new drug design

    Iktos, a company specialized in Artificial Intelligence (AI) for new drug design announced a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain. Unde ... more

    Iktos Announces Collaboration With Pfizer in AI for Drug Design

    Iktos announced the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in small ... more

    Merck cooperates with French start-up

    Merck announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds. “This agreement is another illustration of how we aim t ... more

  • Companies

    Iktos

    Incorporated in October 2016, Iktos is a French start-up company specialized in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on de ... more

More about Zealand Pharma